Walking Impairment In Multiple Sclerosis Therapeutics
1. Ampyra patent expiration
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918973 | MERZ | Sustained release aminopyridine composition |
Dec, 2024
(1 year, 26 days ago) | |
| US8663685 | MERZ | Sustained release aminopyridine composition |
Jan, 2025
(11 months ago) | |
| US8440703 | MERZ | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(9 months ago) | |
| US8354437 | MERZ | Method of using sustained release aminopyridine compositions |
Dec, 2026
(11 months from now) | |
| US5540938 | MERZ | Formulations and their use in the treatment of neurological diseases |
Jul, 2018
(7 years ago) | |
| US8007826 | MERZ | Sustained release aminopyridine composition |
May, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
